Table of Content

1 Bioequivalent Peptide Drugs Market Overview
1.1 Product Overview and Scope of Bioequivalent Peptide Drugs
1.2 Bioequivalent Peptide Drugs Segment by Type
1.2.1 Global Bioequivalent Peptide Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Teriparatide(Forteo)
1.2.3 Teduglutide(Gattex)
1.2.4 Liraglutide(Victoza)
1.3 Bioequivalent Peptide Drugs Segment by Application
1.3.1 Global Bioequivalent Peptide Drugs Market Value by Application: (2024-2034)
1.3.2 Short Bowel Syndrome
1.3.3 Osteoporosis
1.3.4 Type 2 Diabetes
1.3.5 Others
1.4 Global Bioequivalent Peptide Drugs Market Size Estimates and Forecasts
1.4.1 Global Bioequivalent Peptide Drugs Revenue 2018-2029
1.4.2 Global Bioequivalent Peptide Drugs Sales 2018-2029
1.4.3 Global Bioequivalent Peptide Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bioequivalent Peptide Drugs Market Competition by Manufacturers
2.1 Global Bioequivalent Peptide Drugs Sales Market Share by Manufacturers (2018-2024)
2.2 Global Bioequivalent Peptide Drugs Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Bioequivalent Peptide Drugs Average Price by Manufacturers (2018-2024)
2.4 Global Bioequivalent Peptide Drugs Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Bioequivalent Peptide Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bioequivalent Peptide Drugs, Product Type & Application
2.7 Bioequivalent Peptide Drugs Market Competitive Situation and Trends
2.7.1 Bioequivalent Peptide Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bioequivalent Peptide Drugs Players Market Share by Revenue
2.7.3 Global Bioequivalent Peptide Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bioequivalent Peptide Drugs Retrospective Market Scenario by Region
3.1 Global Bioequivalent Peptide Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bioequivalent Peptide Drugs Global Bioequivalent Peptide Drugs Sales by Region: 2018-2029
3.2.1 Global Bioequivalent Peptide Drugs Sales by Region: 2018-2024
3.2.2 Global Bioequivalent Peptide Drugs Sales by Region: 2024-2029
3.3 Global Bioequivalent Peptide Drugs Global Bioequivalent Peptide Drugs Revenue by Region: 2018-2029
3.3.1 Global Bioequivalent Peptide Drugs Revenue by Region: 2018-2024
3.3.2 Global Bioequivalent Peptide Drugs Revenue by Region: 2024-2029
3.4 North America Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.4.1 North America Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.4.3 North America Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.5.1 Europe Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.5.3 Europe Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.7.1 Latin America Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.7.3 Latin America Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bioequivalent Peptide Drugs Sales by Type (2018-2029)
4.1.1 Global Bioequivalent Peptide Drugs Sales by Type (2018-2024)
4.1.2 Global Bioequivalent Peptide Drugs Sales by Type (2024-2029)
4.1.3 Global Bioequivalent Peptide Drugs Sales Market Share by Type (2018-2029)
4.2 Global Bioequivalent Peptide Drugs Revenue by Type (2018-2029)
4.2.1 Global Bioequivalent Peptide Drugs Revenue by Type (2018-2024)
4.2.2 Global Bioequivalent Peptide Drugs Revenue by Type (2024-2029)
4.2.3 Global Bioequivalent Peptide Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Bioequivalent Peptide Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bioequivalent Peptide Drugs Sales by Application (2018-2029)
5.1.1 Global Bioequivalent Peptide Drugs Sales by Application (2018-2024)
5.1.2 Global Bioequivalent Peptide Drugs Sales by Application (2024-2029)
5.1.3 Global Bioequivalent Peptide Drugs Sales Market Share by Application (2018-2029)
5.2 Global Bioequivalent Peptide Drugs Revenue by Application (2018-2029)
5.2.1 Global Bioequivalent Peptide Drugs Revenue by Application (2018-2024)
5.2.2 Global Bioequivalent Peptide Drugs Revenue by Application (2024-2029)
5.2.3 Global Bioequivalent Peptide Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Bioequivalent Peptide Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Eli Lilly and Company
6.1.1 Eli Lilly and Company Corporation Information
6.1.2 Eli Lilly and Company Description and Business Overview
6.1.3 Eli Lilly and Company Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Eli Lilly and Company Bioequivalent Peptide Drugs Product Portfolio
6.1.5 Eli Lilly and Company Recent Developments/Updates
6.2 Alvogen
6.2.1 Alvogen Corporation Information
6.2.2 Alvogen Description and Business Overview
6.2.3 Alvogen Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Alvogen Bioequivalent Peptide Drugs Product Portfolio
6.2.5 Alvogen Recent Developments/Updates
6.3 Pfenex
6.3.1 Pfenex Corporation Information
6.3.2 Pfenex Description and Business Overview
6.3.3 Pfenex Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Pfenex Bioequivalent Peptide Drugs Product Portfolio
6.3.5 Pfenex Recent Developments/Updates
6.4 HEC Pharm
6.4.1 HEC Pharm Corporation Information
6.4.2 HEC Pharm Description and Business Overview
6.4.3 HEC Pharm Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 HEC Pharm Bioequivalent Peptide Drugs Product Portfolio
6.4.5 HEC Pharm Recent Developments/Updates
6.5 Bachem
6.5.1 Bachem Corporation Information
6.5.2 Bachem Description and Business Overview
6.5.3 Bachem Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Bachem Bioequivalent Peptide Drugs Product Portfolio
6.5.5 Bachem Recent Developments/Updates
6.6 Bharat Pharmaceuticals
6.6.1 Bharat Pharmaceuticals Corporation Information
6.6.2 Bharat Pharmaceuticals Description and Business Overview
6.6.3 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.6.5 Bharat Pharmaceuticals Recent Developments/Updates
6.7 Kingpep Biotechnology
6.6.1 Kingpep Biotechnology Corporation Information
6.6.2 Kingpep Biotechnology Description and Business Overview
6.6.3 Kingpep Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Kingpep Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.7.5 Kingpep Biotechnology Recent Developments/Updates
6.8 Ambio Pharmaceuticals
6.8.1 Ambio Pharmaceuticals Corporation Information
6.8.2 Ambio Pharmaceuticals Description and Business Overview
6.8.3 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.8.5 Ambio Pharmaceuticals Recent Developments/Updates
6.9 Jiangsu Sinopep Allsino Biopharmaceutical
6.9.1 Jiangsu Sinopep Allsino Biopharmaceutical Corporation Information
6.9.2 Jiangsu Sinopep Allsino Biopharmaceutical Description and Business Overview
6.9.3 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Product Portfolio
6.9.5 Jiangsu Sinopep Allsino Biopharmaceutical Recent Developments/Updates
6.10 Shanghai Shyndec Pharmaceutical
6.10.1 Shanghai Shyndec Pharmaceutical Corporation Information
6.10.2 Shanghai Shyndec Pharmaceutical Description and Business Overview
6.10.3 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Product Portfolio
6.10.5 Shanghai Shyndec Pharmaceutical Recent Developments/Updates
6.11 Shenzhen Salubris Pharmaceuticals
6.11.1 Shenzhen Salubris Pharmaceuticals Corporation Information
6.11.2 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Description and Business Overview
6.11.3 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.11.5 Shenzhen Salubris Pharmaceuticals Recent Developments/Updates
6.12 Shanghai United Cell Biotechnology
6.12.1 Shanghai United Cell Biotechnology Corporation Information
6.12.2 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Description and Business Overview
6.12.3 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.12.5 Shanghai United Cell Biotechnology Recent Developments/Updates
6.13 Shenzhen JYMed Technology
6.13.1 Shenzhen JYMed Technology Corporation Information
6.13.2 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Description and Business Overview
6.13.3 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Product Portfolio
6.13.5 Shenzhen JYMed Technology Recent Developments/Updates
6.14 Wuxi Asiapeptide Biotechnology
6.14.1 Wuxi Asiapeptide Biotechnology Corporation Information
6.14.2 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Description and Business Overview
6.14.3 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.14.5 Wuxi Asiapeptide Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bioequivalent Peptide Drugs Industry Chain Analysis
7.2 Bioequivalent Peptide Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bioequivalent Peptide Drugs Production Mode & Process
7.4 Bioequivalent Peptide Drugs Sales and Marketing
7.4.1 Bioequivalent Peptide Drugs Sales Channels
7.4.2 Bioequivalent Peptide Drugs Distributors
7.5 Bioequivalent Peptide Drugs Customers
8 Bioequivalent Peptide Drugs Market Dynamics
8.1 Bioequivalent Peptide Drugs Industry Trends
8.2 Bioequivalent Peptide Drugs Market Drivers
8.3 Bioequivalent Peptide Drugs Market Challenges
8.4 Bioequivalent Peptide Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Bioequivalent Peptide Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Bioequivalent Peptide Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Bioequivalent Peptide Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Bioequivalent Peptide Drugs Sales (Units) of Key Manufacturers (2018-2024)
Table 5. Global Bioequivalent Peptide Drugs Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Bioequivalent Peptide Drugs Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Bioequivalent Peptide Drugs Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Bioequivalent Peptide Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Bioequivalent Peptide Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Bioequivalent Peptide Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Bioequivalent Peptide Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Bioequivalent Peptide Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bioequivalent Peptide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bioequivalent Peptide Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bioequivalent Peptide Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Bioequivalent Peptide Drugs Sales by Region (2018-2024) & (Units)
Table 18. Global Bioequivalent Peptide Drugs Sales Market Share by Region (2018-2024)
Table 19. Global Bioequivalent Peptide Drugs Sales by Region (2024-2029) & (Units)
Table 20. Global Bioequivalent Peptide Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Bioequivalent Peptide Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Bioequivalent Peptide Drugs Revenue Market Share by Region (2018-2024)
Table 23. Global Bioequivalent Peptide Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Bioequivalent Peptide Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Bioequivalent Peptide Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Bioequivalent Peptide Drugs Sales by Country (2018-2024) & (Units)
Table 27. North America Bioequivalent Peptide Drugs Sales by Country (2024-2029) & (Units)
Table 28. North America Bioequivalent Peptide Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Bioequivalent Peptide Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Bioequivalent Peptide Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Bioequivalent Peptide Drugs Sales by Country (2018-2024) & (Units)
Table 32. Europe Bioequivalent Peptide Drugs Sales by Country (2024-2029) & (Units)
Table 33. Europe Bioequivalent Peptide Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Bioequivalent Peptide Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Bioequivalent Peptide Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Bioequivalent Peptide Drugs Sales by Region (2018-2024) & (Units)
Table 37. Asia Pacific Bioequivalent Peptide Drugs Sales by Region (2024-2029) & (Units)
Table 38. Asia Pacific Bioequivalent Peptide Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Bioequivalent Peptide Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Bioequivalent Peptide Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Bioequivalent Peptide Drugs Sales by Country (2018-2024) & (Units)
Table 42. Latin America Bioequivalent Peptide Drugs Sales by Country (2024-2029) & (Units)
Table 43. Latin America Bioequivalent Peptide Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Bioequivalent Peptide Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Bioequivalent Peptide Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Bioequivalent Peptide Drugs Sales by Country (2018-2024) & (Units)
Table 47. Middle East & Africa Bioequivalent Peptide Drugs Sales by Country (2024-2029) & (Units)
Table 48. Middle East & Africa Bioequivalent Peptide Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Bioequivalent Peptide Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Bioequivalent Peptide Drugs Sales (Units) by Type (2018-2024)
Table 51. Global Bioequivalent Peptide Drugs Sales (Units) by Type (2024-2029)
Table 52. Global Bioequivalent Peptide Drugs Sales Market Share by Type (2018-2024)
Table 53. Global Bioequivalent Peptide Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Bioequivalent Peptide Drugs Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Bioequivalent Peptide Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Bioequivalent Peptide Drugs Revenue Market Share by Type (2018-2024)
Table 57. Global Bioequivalent Peptide Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Type (2018-2024)
Table 59. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Type (2024-2029)
Table 60. Global Bioequivalent Peptide Drugs Sales (Units) by Application (2018-2024)
Table 61. Global Bioequivalent Peptide Drugs Sales (Units) by Application (2024-2029)
Table 62. Global Bioequivalent Peptide Drugs Sales Market Share by Application (2018-2024)
Table 63. Global Bioequivalent Peptide Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Bioequivalent Peptide Drugs Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Bioequivalent Peptide Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Bioequivalent Peptide Drugs Revenue Market Share by Application (2018-2024)
Table 67. Global Bioequivalent Peptide Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Application (2018-2024)
Table 69. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Application (2024-2029)
Table 70. Eli Lilly and Company Corporation Information
Table 71. Eli Lilly and Company Description and Business Overview
Table 72. Eli Lilly and Company Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Eli Lilly and Company Bioequivalent Peptide Drugs Product
Table 74. Eli Lilly and Company Recent Developments/Updates
Table 75. Alvogen Corporation Information
Table 76. Alvogen Description and Business Overview
Table 77. Alvogen Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Alvogen Bioequivalent Peptide Drugs Product
Table 79. Alvogen Recent Developments/Updates
Table 80. Pfenex Corporation Information
Table 81. Pfenex Description and Business Overview
Table 82. Pfenex Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Pfenex Bioequivalent Peptide Drugs Product
Table 84. Pfenex Recent Developments/Updates
Table 85. HEC Pharm Corporation Information
Table 86. HEC Pharm Description and Business Overview
Table 87. HEC Pharm Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. HEC Pharm Bioequivalent Peptide Drugs Product
Table 89. HEC Pharm Recent Developments/Updates
Table 90. Bachem Corporation Information
Table 91. Bachem Description and Business Overview
Table 92. Bachem Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Bachem Bioequivalent Peptide Drugs Product
Table 94. Bachem Recent Developments/Updates
Table 95. Bharat Pharmaceuticals Corporation Information
Table 96. Bharat Pharmaceuticals Description and Business Overview
Table 97. Bharat Pharmaceuticals Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Bharat Pharmaceuticals Bioequivalent Peptide Drugs Product
Table 99. Bharat Pharmaceuticals Recent Developments/Updates
Table 100. Kingpep Biotechnology Corporation Information
Table 101. Kingpep Biotechnology Description and Business Overview
Table 102. Kingpep Biotechnology Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Kingpep Biotechnology Bioequivalent Peptide Drugs Product
Table 104. Kingpep Biotechnology Recent Developments/Updates
Table 105. Ambio Pharmaceuticals Corporation Information
Table 106. Ambio Pharmaceuticals Description and Business Overview
Table 107. Ambio Pharmaceuticals Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Ambio Pharmaceuticals Bioequivalent Peptide Drugs Product
Table 109. Ambio Pharmaceuticals Recent Developments/Updates
Table 110. Jiangsu Sinopep Allsino Biopharmaceutical Corporation Information
Table 111. Jiangsu Sinopep Allsino Biopharmaceutical Description and Business Overview
Table 112. Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Product
Table 114. Jiangsu Sinopep Allsino Biopharmaceutical Recent Developments/Updates
Table 115. Shanghai Shyndec Pharmaceutical Corporation Information
Table 116. Shanghai Shyndec Pharmaceutical Description and Business Overview
Table 117. Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Product
Table 119. Shanghai Shyndec Pharmaceutical Recent Developments/Updates
Table 120. Shenzhen Salubris Pharmaceuticals Corporation Information
Table 121. Shenzhen Salubris Pharmaceuticals Description and Business Overview
Table 122. Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Product
Table 124. Shenzhen Salubris Pharmaceuticals Recent Developments/Updates
Table 125. Shanghai United Cell Biotechnology Corporation Information
Table 126. Shanghai United Cell Biotechnology Description and Business Overview
Table 127. Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Product
Table 129. Shanghai United Cell Biotechnology Recent Developments/Updates
Table 130. Shenzhen JYMed Technology Corporation Information
Table 131. Shenzhen JYMed Technology Description and Business Overview
Table 132. Shenzhen JYMed Technology Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Shenzhen JYMed Technology Bioequivalent Peptide Drugs Product
Table 134. Shenzhen JYMed Technology Recent Developments/Updates
Table 135. Wuxi Asiapeptide Biotechnology Corporation Information
Table 136. Wuxi Asiapeptide Biotechnology Description and Business Overview
Table 137. Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Product
Table 139. Wuxi Asiapeptide Biotechnology Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Bioequivalent Peptide Drugs Distributors List
Table 143. Bioequivalent Peptide Drugs Customers List
Table 144. Bioequivalent Peptide Drugs Market Trends
Table 145. Bioequivalent Peptide Drugs Market Drivers
Table 146. Bioequivalent Peptide Drugs Market Challenges
Table 147. Bioequivalent Peptide Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Bioequivalent Peptide Drugs
Figure 2. Global Bioequivalent Peptide Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Bioequivalent Peptide Drugs Market Share by Type in 2022 & 2029
Figure 4. Teriparatide(Forteo) Product Picture
Figure 5. Teduglutide(Gattex) Product Picture
Figure 6. Liraglutide(Victoza) Product Picture
Figure 7. Global Bioequivalent Peptide Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Bioequivalent Peptide Drugs Market Share by Application in 2022 & 2029
Figure 9. Short Bowel Syndrome
Figure 10. Osteoporosis
Figure 11. Type 2 Diabetes
Figure 12. Others
Figure 13. Global Bioequivalent Peptide Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Bioequivalent Peptide Drugs Market Size (2018-2029) & (US$ Million)
Figure 15. Global Bioequivalent Peptide Drugs Sales (2018-2029) & (Units)
Figure 16. Global Bioequivalent Peptide Drugs Average Price (US$/Unit) & (2018-2029)
Figure 17. Bioequivalent Peptide Drugs Report Years Considered
Figure 18. Bioequivalent Peptide Drugs Sales Share by Manufacturers in 2022
Figure 19. Global Bioequivalent Peptide Drugs Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Bioequivalent Peptide Drugs Players: Market Share by Revenue in 2022
Figure 21. Bioequivalent Peptide Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Bioequivalent Peptide Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Bioequivalent Peptide Drugs Sales Market Share by Country (2018-2029)
Figure 24. North America Bioequivalent Peptide Drugs Revenue Market Share by Country (2018-2029)
Figure 25. United States Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Bioequivalent Peptide Drugs Sales Market Share by Country (2018-2029)
Figure 28. Europe Bioequivalent Peptide Drugs Revenue Market Share by Country (2018-2029)
Figure 29. Germany Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Bioequivalent Peptide Drugs Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Bioequivalent Peptide Drugs Revenue Market Share by Region (2018-2029)
Figure 36. China Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Bioequivalent Peptide Drugs Sales Market Share by Country (2018-2029)
Figure 44. Latin America Bioequivalent Peptide Drugs Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Colombia Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Bioequivalent Peptide Drugs Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Bioequivalent Peptide Drugs Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Bioequivalent Peptide Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Bioequivalent Peptide Drugs by Type (2018-2029)
Figure 55. Global Revenue Market Share of Bioequivalent Peptide Drugs by Type (2018-2029)
Figure 56. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Bioequivalent Peptide Drugs by Application (2018-2029)
Figure 58. Global Revenue Market Share of Bioequivalent Peptide Drugs by Application (2018-2029)
Figure 59. Global Bioequivalent Peptide Drugs Price (US$/Unit) by Application (2018-2029)
Figure 60. Bioequivalent Peptide Drugs Value Chain
Figure 61. Bioequivalent Peptide Drugs Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed